Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Advanced Macular Degeneration
NCT00896779Phase 2Completed
- Sponsor
- Steven R. Sanislo
- Start
- Oct 2009
- Primary completion
- Sep 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Steven R. Sanislo. Started Oct 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00896779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00896779.